ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 95 filers reported holding ALX ONCOLOGY HLDGS INC in Q1 2021. The put-call ratio across all filers is 0.24 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $248,390 | +21.1% | 51,748 | +89.5% | 0.00% | – |
| Q2 2023 | $205,031 | +78.6% | 27,301 | +7.5% | 0.00% | – |
| Q1 2023 | $114,830 | -95.0% | 25,405 | -87.5% | 0.00% | – |
| Q4 2022 | $2,288,643 | +974.5% | 203,074 | +814.5% | 0.00% | – |
| Q3 2022 | $213,000 | +56.6% | 22,206 | +31.6% | 0.00% | – |
| Q2 2022 | $136,000 | -86.3% | 16,874 | -71.2% | 0.00% | – |
| Q1 2022 | $992,000 | -33.4% | 58,681 | -15.4% | 0.00% | – |
| Q4 2021 | $1,490,000 | +192.7% | 69,325 | +903.8% | 0.00% | – |
| Q3 2021 | $509,000 | +57.6% | 6,906 | +16.9% | 0.00% | – |
| Q2 2021 | $323,000 | +38.6% | 5,907 | +86.0% | 0.00% | – |
| Q1 2021 | $233,000 | -62.0% | 3,175 | -55.3% | 0.00% | – |
| Q4 2020 | $613,000 | +91.0% | 7,110 | -16.5% | 0.00% | – |
| Q3 2020 | $321,000 | – | 8,510 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $715,272,000 | 67.97% |
| Logos Global Management LP | 3,156,981 | $232,796,000 | 22.72% |
| Vivo Capital, LLC | 4,220,048 | $311,186,000 | 10.94% |
| Foresite Capital Management IV, LLC | 785,945 | $57,956,000 | 6.94% |
| Foresite Capital Management V, LLC | 320,000 | $23,597,000 | 6.94% |
| Board of Trustees of The Leland Stanford Junior University | 518,822 | $38,258,000 | 3.38% |
| Cormorant Asset Management, LP | 881,770 | $65,022,000 | 1.45% |
| Redmile Group, LLC | 978,600 | $72,162,000 | 1.02% |
| SPHERA FUNDS MANAGEMENT LTD. | 130,351 | $9,612,000 | 0.74% |
| Artal Group S.A. | 525,000 | $38,714,000 | 0.68% |